CD7 Antibody

CD7, a cell surface glycoprotein, plays a significant role in various immune and hematologic processes. Its expression and functionality have been implicated in:

• **Leukemia:** CD7 positivity is significantly associated with FLT3 positivity in acute myeloid leukemia patients. (PMID: 25679063)
• **B-cell Acute Lymphoblastic Leukemia (B-ALL):** CD7 promotes extramedullary involvement in B-ALL cell lines through its interaction with integrin beta2. (PMID: 24920488)
• **Adult T-cell Leukemia/Lymphoma (ATLL):** The CADM1 versus CD7 plot distinguishes clonally expanding HTLV-I-infected cells in various stages of ATLL. (PMID: 24727323)
• **Melanoma:** CD7 is present on monocytes and tumor macrophages, and its ligand, SECTM1, is frequently expressed in corresponding melanoma tissues. (PMID: 24157461)
• **Hematopoiesis:** SECTM1 secreted from bone marrow stromal cells may interact with CD7 to influence GM-CSF expression in leukemic cells. (PMID: 24211252)
• **Epigenetic Regulation:** Epigenetic down-regulation of CD7 is associated with acute myeloid leukemia. (PMID: 20398252)
• **Natural Killer Cell Leukemia:** CD7 loss is a potential diagnostic marker for aggressive natural killer-cell leukemia. (PMID: 20046078)
• **T-cell Lymphomas:** Low CD7 expression in T-cell lymphomas is linked to Twist2-mediated suppression of promoter activity but can be enhanced by histone deacetylase inhibitors. (PMID: 19937140)
• **Chronic Myeloid Leukemia (CML):** Epigenetic modifications are associated with CD7 expression in primitive CML cells. (PMID: 20175919)
• **Lineage Commitment:** CD7 expression in hematopoietic cells indicates commitment to B-cell and natural killer cell lineages. (PMID: 12393702)
• **Inositol Phosphate Turnover:** CD7 interacts with type II phosphatidylinositol-4 kinase, a key component in inositol phosphate turnover pathways. (PMID: 12594831)
• **Targeted Therapy:** A novel fusion protein, scFvCD7:sFasL, has been designed for leukemia-restricted therapeutic activity. (PMID: 16332967)
• **Disease Prognosis:** Patients with CD7 expression exhibit shorter disease-free and post-remission survival compared to those without CD7 expression. (PMID: 16837044)
• **Lung Microvascular Endothelial Cells (LME):** CD7 is expressed in LME cells and acts as an Fc receptor for IgM. (PMID: 16990185)
• **Calcium Signaling:** HTLV-I-infected cells exhibit decreased intracellular calcium levels in response to ionomycin, which is correlated with decreased CD7 expression. (PMID: 17287851)
• **Thymus Development:** Differential levels of CD7 identify the progressive stages of lineage commitment in the thymus, originating from a primitive CD7(-) lympho-myeloid thymic progenitor. (PMID: 17959857)
• **FLT3/ITD Mutation:** Aberrant CD7 expression is closely associated with the FLT3/ITD mutation in acute myeloid leukemia, suggesting that FLT3/ITD-mediated leukemic transformation occurs at an early stage of myeloid progenitor cells. (PMID: 18343790)
• **Hodgkin Lymphoma (HL):** CD7 expression in CD4(+) T cells distinguishes between HL and reactive LAD, potentially aiding in HL diagnosis. (PMID: 18956470)
• **ATLL Progression:** Down-regulation of CD7 may enable ATLL cells to escape Gal-3-induced apoptosis, contributing to a more aggressive clinical course. (PMID: 19207946)
• **T-cell Targeting:** The galectin-1 glycoprotein receptor CD7 might serve as a novel target for GdA on T cells. (PMID: 19683346)

HGNC: 1695

OMIM: 186820

KEGG: hsa:924

STRING: 9606.ENSP00000312027

UniGene: Hs.36972